<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Public health and clinical screening for Chagas disease in the United States</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Public health and clinical screening for Chagas disease in the United States</h1>
<div class="graphic"><div class="figure"><div class="ttl">Public health and clinical screening for Chagas disease in the United States</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Target population</td> <td class="subtitle1">Screening methods</td> <td class="subtitle1">Primary goal</td> <td class="subtitle1">Secondary goal</td> <td class="subtitle1">Intervention details and effectiveness</td> <td class="subtitle1">Published estimates of Chagas disease prevalence</td> </tr> <tr> <td>Blood donors</td> <td>Serology</td> <td>Prevent transmission</td> <td>Refer infected persons for management</td> <td>Discard screen-positive donations; highly effective</td> <td>Approximately 1/15,000 first-time donors, up to 1/2700 in high-risk <span class="nowrap_whitespace">areas<sup>[1]</sup></span></td> </tr> <tr> <td>Organ donors</td> <td>Risk-based*, serology</td> <td>Prevent transmission</td> <td> </td> <td>Heart from infected donor not used; use of other organs with appropriate monitoring; highly effective</td> <td>0.9% in combined risk-based and serologic donor <span class="nowrap_whitespace">screening<sup>[2]</sup></span></td> </tr> <tr> <td>Pregnant females from Latin America; infants born to infected mothers</td> <td>Maternal serology, serial testing of infants<sup>¶</sup>; serology in siblings</td> <td>Detect and treat infected infants early in life</td> <td>Refer infected mothers and their other children for treatment</td> <td>Early treatment of infants; treatment of mothers after lactation ends; treat infected siblings; highly effective in infants and children, moderate in young mothers</td> <td>Approximately 10 mothers and &lt;1 infected child per 4000 high-risk females (majority born in Latin <span class="nowrap_whitespace">America)<sup>[3]</sup></span></td> </tr> <tr> <td>Immigrants from Latin <span class="nowrap_whitespace">America<sup>Δ</sup></span> and individuals with other risk factors*</td> <td>Risk-based*, serology</td> <td>Detect asymptomatic infected individuals</td> <td>Refer family members at <span class="nowrap_whitespace">risk<sup>◊</sup></span></td> <td>Treatment of infected individuals; effectiveness high in children, uncertain in adults</td> <td>0.5 to 4% in high-risk populations; many of those detected were &gt;50 in whom treatment not generally <span class="nowrap_whitespace">recommended<sup>[4-6]</sup></span></td> </tr> <tr> <td>Patients from Latin America with immunosuppressive conditions (HIV, transplant candidates, transplant recipients)</td> <td>Serology; molecular testing if high index of suspicion</td> <td>Detect infected individuals before reactivation occurs</td> <td> </td> <td>Treatment of <em>Trypanosoma cruzi</em> reactivation can be life-saving; prospective monitoring for reactivation improves prognosis</td> <td>No systematic data on prevalence of <em>T. cruzi</em> in these populations in the United States</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>* Risk factors include being born or having lived ≥6 months in an endemic country of Latin America, persons born to a mother with confirmed <em>T. cruzi</em> infection, or persons with evidence of a bite or other exposure to a triatomine bug in Latin America or regions of United States with known enzootic cycles.</p>
<p>¶ Polymerase chain reaction (plus microscopy if available) twice in the first 3 months of life, followed by immunoglobulin G serology at 9 months or later.</p>
<p>Δ Highest priority for children, young adults, and females of childbearing age due to considerations of antitrypanosomal treatment <span class="nowrap_whitespace">effectiveness<sup>[7]</sup>.</span></p>
◊ Family members of infected individuals should also be tested if they share the same risk factors, such as residence in an endemic <span class="nowrap_whitespace">country<sup>[8]</sup>.</span></div><div class="graphic_reference">References:
<ol>
<li>Dodd RY, Groves JA, Townsend RL, et al. Impact of one‐time testing for Trypanosoma cruzi antibodies among blood donors in the United States Transfusion 2019; 59:1016.</li>
<li>Schwartz BS, Paster M, Ison MG, Chin-Hong PV. Organ donor screening practices for Trypanosoma cruzi infection among US Organ Procurement Organizations. Am J Transplant 2011; 11:848.</li>
<li>Edwards MS, Rench MA, Todd CW, et al. Perinatal Screening for Chagas Disease in Southern Texas. Journal of the Pediatric Infectious Diseases Society 2015; 4:67.</li>
<li>Manne-Goehler J, Davis J, Perez JH, et al. The results of a primary care-based screening program for Trypanosoma cruzi in East Boston, Massachusetts. In: IDWeek. San Francisco, CA:2018. Available at: <a href="https://doi.org/10.4269/ajtmh.abstract2018" target="_blank">https://doi.org/10.4269/ajtmh.abstract2018</a>.</li>
<li>Meymandi SK, Forsyth CJ, Soverow J, et al. Prevalence of Chagas Disease in the Latin American-born Population of Los Angeles. Clin Infect Dis 2017; 64:1182.</li>
<li>Castro-Sesquen YE, Saldana A, Patino Nava D, et al. Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area. Clin Infect Dis 2021; 72:e303.</li>
<li>Forsyth CJ, Manne-Goehler J, Bern C, et al. Recommendations for Screening and Diagnosis of Chagas Disease in the United States. J Infect Dis 2021; jiab513.</li>
<li>Hernandez S, Forsyth CJ, Flores CA, Meymandi SK. Prevalence of Chagas Disease Among Family Members of Previously Diagnosed Patients in Los Angeles, California. Clin Infect Dis 2019; 69:1226.</li>
</ol></div><div id="graphicVersion">Graphic 138385 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
